Align Technology Q3 2026: EPS up 144% to $1.90 on easy comparisons; full-year sales outlook cut to about 2%

Align Technology, the maker of Invisalign clear aligners and iTero dental scanners, reported third-quarter 2026 diluted earnings per share (EPS) of $1.90, up from $0.78 a year ago, on revenue that rose just 1.9% to $1,014.8 million. The EPS jump mostly reflects how bad the comparison quarter was rather than a step change in the business: Q3 2025 carried $88.3 million of impairments, write-downs and restructuring and a 40.1% tax rate. On the company's own adjusted basis, EPS rose 7.3% to $2.80. The more important news is in the outlook: Align now expects full-year 2026 revenue of $4,110–4,130 million, roughly 2% growth on 2025's $4,035.0 million, down from the 3–4% it guided to in July, and its fourth-quarter range implies sales below a year ago. The same day, Align named Jennifer Davis, formerly head of Procter & Gamble's global healthcare business, to succeed Joe Hogan as CEO on December 31, 2026.

This analysis is written from the earnings release (Exhibit 99.1 to the 8-K filed October 28, 2026). The full 10-Q is not filed yet, so segment operating margins, revenue by region, the teen case count and management's line-by-line explanation of what moved are not available here.

Source: Align Technology Q3 2026 earnings release, Exhibit 99.1 to Form 8-K filed October 28, 2026. "pp" = percentage points. "Non-GAAP" figures are the company's adjusted measures, which leave out stock-based pay, amortization of acquired intangibles, restructuring, legal charges and other items it treats as one-offs.

Volume up, price down

Align's business has two parts. Clear aligners (Invisalign) are about 83% of revenue; the rest is iTero intraoral scanners — the handheld cameras dentists use to take a 3D image of the teeth instead of a physical mould — plus exocad design software.

On the aligner side, the number of doctors who shipped at least one case hit a record 90,910, up 3.1% from 88,155, and each of them shipped slightly more (7.6 cases per doctor versus 7.3). Management also says North American orthodontist shipments grew year over year "for the first time in 6 quarters" and that shipments through dental service organizations (DSOs — corporate chains that run many dental practices) were up double digits. Those are real demand signals in a market the CFO describes as still "affected by a softer environment for discretionary healthcare spending."

The problem is price. Revenue per case shipped — Align's own measure, clear aligner revenue divided by cases, and the closest thing the release gives to an average selling price (ASP) — fell to $1,215 from $1,245 a year earlier and from $1,260 in Q2. Currency explains only a small part: the stronger dollar took about $4.1 million, or 0.5%, off aligner revenue. In constant currency — what revenue would have been at last year's exchange rates — aligner revenue grew about 4.7% against 6.6% more cases. The CEO attributes the softer margin to "lower Clear Aligner ASPs and geographic and product mix," meaning more cases are coming from lower-priced countries and lower-priced product versions. The 10-Q, not yet filed, is where Align normally splits this between discounting, mix and currency.

Scanners: more units, less revenue

Imaging Systems and CAD/CAM Services revenue fell 7.6% to $175.5 million (about 7.1% in constant currency), even though Align says scanner units placed, including leased, rented and certified pre-owned systems, grew double digits to more than 157,000 in the field. That is the same pattern as Q2: dentists are getting cheaper scanners or leasing rather than buying, which spreads revenue over time instead of booking it up front. Align is choosing this deliberately, on the view that every scanner in a practice feeds future aligner cases, but in the meantime this part of the business is shrinking in dollars.

What the headline numbers hide

• The year-ago quarter was full of charges. Q3 2025 included a $23.1 million impairment on a manufacturing site held for sale, $14.9 million of obsolete-inventory write-offs, $13.7 million of accelerated depreciation on equipment being retired and $36.6 million of restructuring — $88.3 million in all. Q3 2026 had $28.5 million of restructuring under a new 2026 headcount plan and a $6.6 million legal line ($5.6 million more for the UK VAT dispute plus $1.0 million of settlements). Add those back to pretax income in both years and the gain shrinks from +79.5% to about +12% ($205.2 million versus $183.1 million).
• Tax did a lot of the work. The GAAP effective tax rate — the share of pretax profit paid in tax — fell to 20.6% from 40.1%. At last year's rate, Q3 2026 tax would have been about $33 million higher, roughly $0.47 per share. The release gives no reason for last year's high rate; Align's own adjusted figures assume a flat 20% in both years.
• The adjusted gap is mostly recurring cost. Non-GAAP EPS of $2.80 is $0.90 above GAAP. The single biggest item excluded is $39.0 million of stock-based compensation, which is a real, recurring cost of paying employees; it actually fell from $48.4 million a year ago, which itself helps this year's GAAP comparison.
• Fewer shares added about 2 points. Align bought back 627,300 shares in the quarter at an average of $164.73, about $103.3 million (derived from the release's share count and price; the quarter's cash-flow line isn't disclosed separately). Diluted shares fell 1.9%, which is most of the gap between adjusted net income growth (+5.2%) and adjusted EPS growth (+7.3%). Align pays no dividend.
• Cash is solid. Operating cash flow was $526.7 million for nine months versus $370.0 million a year ago; for the third quarter alone (nine months minus the first half's $343.8 million) it was about $182.9 million, comfortably above $135.0 million of net income. Cash ended at $1,144.9 million with the $300 million credit line undrawn.
• One balance-sheet line to check in the 10-Q. Deferred revenue — money already collected for products and services not yet delivered — fell to $1,162.1 million from $1,261.8 million at year-end. The release doesn't explain it; for a company shifting scanners toward leases and aligners toward cheaper configurations, it's worth reading the 10-Q's breakdown.
• Against its own July guidance, Q3 landed in range. Revenue of $1,014.8 million was inside the $1,000–1,020 million range; GAAP operating margin of 16.7% beat the 13.5%–15.0% range because one-time charges came in at about $35 million, the bottom of the $35–50 million expected; non-GAAP gross margin of 70.4% missed the "approximately 71.0%" target, which the CEO blames on "higher fuel-related transportation costs" plus ASP and mix.

On balance the quarter is flattered: GAAP EPS up 144% overstates the change in the business, because last year's $88.3 million of charges didn't recur and the tax rate halved. Underlying pretax profit grew about 12% and adjusted EPS 7.3% on revenue up 1.9%.

Takeaway: Align is adding patients but not revenue: cases rose 6.6% while revenue per case fell 2.4% and scanner revenue fell 7.6%, so total sales grew 1.9% and the full-year outlook drops to about 2% from 3–4%. Profit growth now depends on cost cuts and buybacks, not on the top line.

Did last time's read hold up?

Our Q2 2026 analysis called Align "a volume-and-cost story rather than a pricing story" and set out "mid-single-digit revenue growth with high-single-digit case growth and flat ASPs" as the base case, warning that tariff refunds and the end of accelerated depreciation would not repeat at the same size. The volume-and-cost read held — cases +6.6%, non-GAAP operating margin up on lower costs — but the base case was too generous: revenue grew 1.9%, not mid-single digits, and revenue per case fell 2.4% rather than holding flat. Non-GAAP gross margin fell to 70.4% from 72.3% in Q2, consistent with those Q2 tailwinds fading. Two items we flagged are still open and not mentioned in the release: the US International Trade Commission judge's initial determination on Angelalign (due November 20, 2026) and the patent board's decisions in the Straumann/ClearCorrect inter partes reviews (due by November 9, 2026). The UK VAT dispute cost another $5.6 million this quarter.

New CEO from consumer health

In a separate release, Align said Jennifer L. Davis, most recently CEO of Procter & Gamble's Global Healthcare business (which includes oral-health brands), joins as CEO-elect and a board member on November 2, 2026 and becomes President and CEO on December 31, 2026. Joe Hogan, CEO since 2015, steps down from the role then and leaves the board after its June 16, 2027 strategy meeting. The chairman frames her background as building "trusted consumer-healthcare brands," which matches where Align's growth is now coming from: more patients and more doctors at lower prices per case.

Outlook

Management's guidance from the release:

• Q4 2026: revenue $1,000–1,020 million; clear aligner volume up low single digits and ASP down about 1% year over year; Systems & Services revenue $170–180 million; GAAP operating margin about 20.0% and non-GAAP about 26.0%; buybacks up to $300 million.
• Full-year 2026: revenue $4,110–4,130 million (July: growth of 3%–4%, which on 2025's $4,035.0 million would have been about $4,156–4,196 million); clear aligner volume and revenue up about 5%–6% (July: volume up about 6%); Systems & Services revenue $715–725 million; GAAP operating margin about 16.2% (July: 15.1%–15.6%); non-GAAP operating margin about 23.7%, unchanged; capex $125–150 million; buybacks about $500 million, the top of July's $400–500 million range.
• 2027: preliminary planning assumes conditions "broadly consistent with current conditions" and "does not require a consumer recovery," with GAAP and non-GAAP operating margins expected to improve by about 100 basis points (1 percentage point).

The guidance cut is on revenue only; the margin target held, so Align is protecting profit with cost cuts as sales slow. Note that the July revenue guide assumed currency would add about 1 point to growth, while in Q3 the dollar was a 0.5% drag — part of the cut is exchange rates rather than demand, though the release doesn't quantify how much. Q4 revenue is guided below the year-ago quarter even with aligner volume still growing. Our read: as long as each case keeps getting cheaper and scanners keep moving to leases, mid-single-digit case growth turns into low-single-digit revenue growth at best, and EPS growth in 2027 will rest on the promised 1-point margin gain and a shrinking share count. Things to watch in the 10-Q and Q4 report: the split of the ASP decline between discounts, mix and currency; whether deferred revenue keeps falling; the November 20 ITC ruling on Angelalign; and whether the incoming CEO changes the pricing or cost plan.